Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by newfer23on Apr 07, 2020 4:43pm

149 Views

Post# 30888056

RE:RE:RE:RE:RE:RE:RE:RE:SHRM the way to go

No argument from me about over prescribing. Ethics aside, consider the profits that have been made from exploiting the properties of that plant. The same can be said of marijuana. On a related note, over prescription of said pain meds has resulted in an opioid addiction epidemic. Which I believe is something researchers are looking to treat with psilocybin.

Bullboard Posts

The Market Online’s Weekly Gold Report – Nov. 13, 2024